Manufacturing

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

BioPharma Connections is an independent, woman-owned consulting firm founded in San Francisco in 2007, providing strategic business development, technical operations, regulatory, product development, and commercialization support to the life sciences industry. Serving pharmaceutical, biotechnology, medical device, and diagnostic companies globally, the firm specializes in facilitating connections between organizations, service providers, CROs, CDMOs, and investors—guiding clients from concept to commercialization, with deep expertise in regulatory compliance, emerging technologies, and diverse therapeutic areas.

Advanced BioScience Laboratories, Inc. (ABL) is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics, and other biologic products. ABL leverages its expertise in product development, GMP manufacturing, and immunological testing to support the development of candidate vaccines and therapeutics through preclinical and clinical stages. The company is involved in producing and testing oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines.

Revolution Biomanufacturing Inc. (RBIx) is expanding beyond traditional CDMO Process/Analytical Development and Manufacturing services to pioneer distributed molecular manufacturing. A new class of digital biomanufacturing that enables the autonomous design, manufacture, quality verification, and deployment of Nucleic Acid therapeutics and molecular diagnostics at the point of need. By integrating AI-driven sequence optimization, enzymatic nucleic acid synthesis, Nanoparticle design and manufacturing (LNP & EV), closed-loop quality control, and field-deployable manufacturing platforms, RBIx is creating adaptive biological infrastructure capable of responding to emerging diseases, national security threats, and personalized medicine with unprecedented speed and flexibility.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

ETC Innovation is a vertically integrated MedTech development company specializing in the design, development, and manufacturing of advanced wound dressing materials, antimicrobial substrates, and infection control products. The company brings together expertise in materials science, manufacturing processes, and regulatory compliance, offering solutions from concept through production for the medical industry. ETC Innovation operates a US-based facility supporting pilot to commercial-scale production, with a focus on custom materials for wound care and infection control. The company invests in R&D and holds equity in several early-stage medical device companies, and it provides proprietary material formulations, process development, and confidential research partnerships.

Sunflower Therapeutics is a women-owned and led biotechnology public benefit corporation founded in 2018, dedicated to democratizing access to protein manufacturing worldwide. The company develops next-generation, automated, and fully-integrated protein manufacturing solutions that simplify the process from discovery to full-scale biomanufacturing. Their mission is to make high-quality, cost-effective therapeutics, vaccines, and protein-based products accessible globally, especially in low- and middle-income countries, by leveraging innovative technologies, sustainable practices, and intuitive equipment. Sunflower’s vision is to transform the global health landscape by enabling more medicines and protein products to reach patients and consumers everywhere. Their core technologies include efficient microbial hosts, data-driven process development, and modular manufacturing facilities, supporting agile, rapid, and cost-effective production cycles for a wide range of protein-based products.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Exponent is a multidisciplinary science and engineering consulting firm serving sectors including healthcare, energy, manufacturing, and consumer products. From medical devices, pharmaceuticals, and supplements to digital health and wearables, we deliver rigorous science that quantifies impacts on human health. Exponent helps you push the envelope on the development, deployment, safety, and effectiveness of cutting-edge drugs, devices, and diagnostics — concomitantly balancing benefits and risks. Count on our multidisciplinary, data-driven, evidence-based assessments to give you clarity on your most complex product needs and challenges. With lives on the line, innovations that support healthcare demand the highest levels of scientific rigor. Whether you’re developing a novel drug, a sturdier stent, or a faster flu test, you need clear answers to complex questions, quickly. Exponent supports our life sciences clients across the total product lifecycle by solving critical design, regulatory, safety, and market access challenges. We can collaborate with you throughout your journey, helping you navigate risks and opportunities — and optimize outcomes — with science-based strategies and specialized expertise.

Simbex is a leading partner in medical device and consumer health product design and development, recognized for transforming complex ideas into commercially successful solutions. With a multidisciplinary team, Simbex excels in engineering, product design, software, data analytics, and commercialization strategy, supporting innovators from concept to market. Their mission is to deliver impactful medical devices and consumer health products that improve health outcomes and quality of life. Simbex is known for its holistic approach, deep regulatory expertise, and commitment to innovation and excellence in the health technology sector. The company is also active in thought leadership, regularly publishing regulatory and reimbursement updates, and hosting educational webinars for the MedTech community. Simbex maintains a robust Quality Management System compliant with ISO 13485 and FDA 21 CFR 820, ensuring high standards in product development. The company is also committed to supporting diversity in MedTech, including initiatives for women in the sector. Simbex's leadership and advisory team bring decades of experience in biomedical engineering, commercialization, regulatory affairs, and technology innovation, further strengthening its position as a trusted partner in the MedTech ecosystem.

Blood Centers of America (BCA) is the largest blood supply network in the United States, comprising over 60 independent community blood centers that collectively distribute approximately 50% of the nation's blood supply. BCA supports member organizations through supply chain solutions, donor recruitment, advocacy, disaster response, and purchasing power. In addition to providing whole blood, red blood cells, platelets, plasma, cells, and tissues for therapeutic, diagnostic, research, and advanced therapy applications, BCA and its network are engaged in the development and delivery of advanced therapies including cell and gene therapy starting materials, processing, and manufacturing. BCA actively mobilizes resources in response to national emergencies, pandemics, and technological advances in donor experience and biotherapeutics.

Solventum is a healthcare company dedicated to enabling better, smarter, and safer healthcare solutions. With a legacy of innovation, Solventum focuses on improving patient outcomes through advanced medical technologies, oral care solutions, health information technology, and purification and filtration systems.

CellBios is a biotechnology company specializing in the design, development, and manufacturing of single-use bioprocessing and medical device solutions for healthcare, biotechnology, and regenerative medicine sectors. The company operates GMP and ISO-certified cleanroom facilities, offering a comprehensive portfolio of cryopreservation products, bioreactors, fluid management systems, advanced packaging, and specialty devices. By leveraging expertise in extrusion, molding, assembly, sterilization, quality control, and regulatory compliance, CellBios provides customized, scalable solutions to support blood transfusion, cell and gene therapy, biologics manufacturing, and clinical workflows.

Michigan Engineering combines top-tier engineering education with advanced research and state-of-the-art facilities, supporting both undergraduate and graduate students. The college emphasizes hands-on and experiential learning, interdisciplinary collaboration, and research strengths in areas such as robotics, energy, sustainability, precision medicine, cybersecurity, space systems, and computational science. Advanced laboratories are available for internal and external users, reflecting a commitment to innovation, industry partnerships, and technology transfer.

New Horizon Medical Solutions is a national advanced wound-care platform delivering biologics, devices, diagnostics, clinical education, reimbursement support, and operational infrastructure to outpatient, post-acute, surgical, and wound-care providers. The company partners with leading manufacturers and healthcare organizations to support compliant adoption of advanced wound-care technologies across the full care continuum.

Aroa Biosurgery Incorporated is wholly owned by Aroa Biosurgery Limited, a New Zealand-based healthcare company specializing in the development, manufacture, and distribution of advanced bioscaffold devices for soft tissue repair and wound management. Utilizing extracellular matrix (ECM) biomaterials, the company offers solutions for chronic wounds, surgical reconstruction, and dead-space management. Products are distributed internationally and supported by clinical evidence, regulatory approvals in 50+ countries, and a strong commercial presence in the US and Europe. The company maintains ISO 13485:2016 and MDSAP certifications and is publicly listed on the Australian Securities Exchange.

ReliOx Corporation is a U.S.-based advanced materials and medical technology company with a clean oxidation platform for on-demand generation of pH-neutral aqueous chlorine dioxide. The ReliOx platform enables safe, controlled oxidation at the point of use without acids, electricity, or hazardous intermediates—addressing long-standing limitations that have historically prevented chlorine dioxide from being used routinely in medical and operational environments. ReliOx directly supports the important core objectives aligned with MTEC members: improving trauma care, reducing infection risk, enabling care in austere and resource-constrained settings, and accelerating transition of dual-use technologies from non-regulated markets into regulated medical and defense applications. The platform’s defining feature is not a new chemical agent, but a novel generation method that produces true chlorine dioxide only at the moment of use, in a neutral pH aqueous form compatible with tissue, metals, polymers, elastomers, and sensitive electronics. ReliOx is advancing an initial wound cleansing and irrigation use case that aligns closely with military and emergency medicine needs, including contaminated wounds, blast injuries, and prolonged field care. The system’s on-demand architecture eliminates the need to store reactive disinfectants, reduces logistical burden, and supports distributed medical operations, a priority across DoD, BARDA, and ONR programs. This makes the platform particularly relevant for battlefield medicine, forward surgical teams, and humanitarian or disaster response scenarios. In parallel, ReliOx operates VetiOx, a veterinary-focused pathway that applies the same platform to animal wound care (including equine). This strategy generates early operational data and clinician familiarity while remaining aligned with long-term human medical translation—an approach consistent with MTEC’s emphasis on de-risking technologies prior to advanced development. The ReliOx platform is inherently dual-use. All commercial, veterinary, food safety, and medical applications share the same resin-based generation mechanism, enabling efficient manufacturing, rapid scaling, and consistent safety characteristics across use cases. This platform approach allows ReliOx to support incremental transition from non-regulated and veterinary markets into FDA-regulated medical devices and DoD-relevant medical countermeasures without fundamental redesign. ReliOx represents a strong MTEC-aligned opportunity at the intersection of advanced chemistry, trauma care, infectious disease mitigation, and distributed manufacturing. The company offers a defensible intellectual property position, a clear regulatory strategy, and a near-term path to operational relevance for military medicine and biodefense stakeholders .

ATD Emolda has been delivering innovative solutions for 40 years, specializing in the conversion and manufacturing of components and assemblies for industrial, medical, and pharmaceutical applications. The company has become a thought leader in advanced wound care materials, focusing on developing high-performance polyurethane foams and silicone adhesives.

Viscus Biologics LLC specializes in product realization from ideation to high volume production, manufacturing components, devices, and products with natural polymer and extracellular matrix materials. The company aims to fulfill patient and market needs, improve quality of life, and restore tissue to a healthy state.

Regencor is a biotechnology company developing regenerative therapeutic solutions for cardiac repair following myocardial infarction. The organization advances a proprietary biologic that stimulates regeneration of heart muscle cells, aiming to restore cardiac function, reduce scar tissue, and prevent heart failure. The company emphasizes non-invasive, outpatient administration of its lead recombinant protein, with a translational approach guided by demonstrated preclinical efficacy and safety. Founded as a spin-out from Stanford University, Regencor is supported by grants from major institutions and has an experienced leadership and scientific advisory board.

Lynch Regenerative Medicine specializes in regenerative biotherapeutics focusing on platelet-derived growth factor (PDGF) for wound healing, soft tissue, and bone regeneration. The company demonstrates expertise in recombinant protein engineering, clinical development, and regulatory submission of PDGF-based therapies for medical, dental, and aesthetic applications. The leadership is comprised of experts in growth factor science and translational medicine with an extensive record of scientific publication, patents, and FDA approvals.

Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.

Instant Systems specializes in the design and manufacture of single-use sterile systems for cell and gene therapy, regenerative medicine, tissue banking, and related bioprocessing applications. The company offers a wide range of customizable solutions for cell culturing, fluid management, media and waste containment, magnetic cell separation, and sterile filtration, with a focus on maintaining process integrity from production through delivery. Their products support closed-system workflows, scalability, and integration into existing manufacturing and research environments.

LSU Health Sciences Center New Orleans is dedicated to educating future health professionals and scientists, advancing research, and providing exceptional healthcare. With six professional schools and numerous affiliated hospitals, LSUHSC-NO aims to improve health outcomes and address health equity challenges in Louisiana.

Vira Regen is pioneering electrogenetics—a new class of bioelectronic medicine that uses precision electrical signals to modulate gene expression and activate the body’s natural regenerative pathways. Our platform is designed to move beyond conventional electrical stimulation by targeting specific genetic and biological pathways involved in tissue repair and regeneration. By combining bioelectric stimulation with computational biology, transcriptomic profiling, and signal discovery, Vira Regen is developing noninvasive therapies that can precisely influence cellular behavior at the site of injury. Our lead program, OsteoVolt™, is a noninvasive bioelectronic bone regeneration technology designed to accelerate healing of fresh and nonunion fractures. Preclinical studies have demonstrated accelerated bone regeneration and fracture healing, and the program is advancing through large-animal validation toward a Class II 510(k) regulatory pathway. Beyond bone regeneration, Vira Regen is building its electrogenetic therapeutic modality as a platform technology for regenerative medicine, with potential applications across musculoskeletal disease, osteoporosis, osteoarthritis, oncology, and healthy longevity. Our vision is to create a new generation of medicines that don't simply treat disease—they use the body's own biological signaling systems to regenerate and restore function.

Kindeva Drug Delivery is a contract development and manufacturing organization specializing in advanced drug delivery systems including pulmonary, nasal, injectable, transdermal, and intradermal therapies. Services range from formulation and analytical development to commercial-scale, Annex 1-compliant GMP manufacturing across global facilities. The company brings integrated expertise in regulatory strategy, device engineering, process and technology transfer, and quality assurance, with a focus on sustainable solutions such as low-GWP propellants and microneedle patch platforms. Kindeva supports complex, patient-centric, and environmentally optimized therapies from product conception through commercialization.

Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite regenerative implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants, launching in orthopedics/tendons and ligaments. The company driven by a team of visionary entrepreneurs and leading bioscientists and engineers.

Cook MyoSite, a subsidiary of Cook Group, has been advancing human muscle cell technology since 2002. Operating under ISO 9001:2015-certified quality standards, we specialize in primary human skeletal muscle-derived cells and fibro-adipogenic progenitors sourced from healthy donors and individuals with neuromuscular, metabolic, and rare disorders. Our offerings include custom cell procurement, specialized media formulations, and contract manufacturing services—supporting both academic research and clinical development in regenerative medicine. Beyond research tools, Cook MyoSite is pioneering autologous muscle-derived cell therapies. Our investigational product, iltamiocel, is currently in a Phase III clinical trial for fecal incontinence, demonstrating our commitment to translating cell-based science into real-world solutions. With expertise in GMP manufacturing, analytical testing, and tailored partnerships, we empower collaborators to accelerate innovation in musculoskeletal and neuromuscular health worldwide.

SK pharmteco is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors with integrated solutions spanning small molecule synthesis, peptides, advanced modalities, and viral vector manufacturing. The company operates CGMP facilities across the US, Europe, and Asia, supporting clients from preclinical to commercial supply. Its offerings include process and analytical development, custom manufacturing, regulatory support, cell and viral banking, and the application of sustainable practices throughout the product lifecycle. Environmental responsibility, compliance, and innovation in manufacturing and analytics are core to their operations.

Matregenix is a global leader in nanofiber technology, specializing in highly customizable nanofibrous materials for diverse applications, particularly in filtration and biomedical fields. The company is committed to pushing the boundaries of nanofiber technology through innovative platforms and state-of-the-art electrospinning machines, providing comprehensive contract development and manufacturing services to help manufacturers bring their innovations to market.

Imperial College London is a world-leading university focused on science, technology, engineering, medicine, and business. It is dedicated to addressing global challenges through innovative research and education, fostering a diverse and inclusive community of students and staff.

Houston Methodist Academic Institute integrates advanced clinical research, education, and healthcare innovation with a focus on translating scientific discoveries into improved patient outcomes. The institute offers accredited graduate and postgraduate medical education, supports interdisciplinary research in major areas such as cancer, cardiology, neuroscience, transplant medicine, and regenerative medicine, and provides extensive infrastructure for digital health and medical technology development. Training and fellowship programs span from medical residencies and fellowships to doctoral and research-oriented positions, supported by collaborations with leading academic and industry partners. The institute leverages core technology platforms, simulation centers, and comprehensive educational pathways to foster future leaders in medicine and biomedical research.

SereNeuro Therapeutics is focused on discovering and developing advanced therapies for pain relief, emphasizing non-opioid solutions. The company is committed to pioneering innovative treatments to address unmet medical needs in pain management.

Signature Science, LLC is a multidisciplinary applied science and technology company dedicated to solving the toughest forensic, biosecurity, and public health challenges. Serving both government and commercial clients, Signature Science combines scientific rigor with proven quality assurance to enhance the credibility and defensibility of programs in national security, public safety, and health security. The company is recognized for its innovation, technical excellence, and commitment to advancing the state-of-the-art in forensic science, genomics, and biosecurity technologies. Signature Science also offers advanced bioinformatics and microbiome analysis services, empowering clients with data-driven insights to address emerging threats, pandemics, and bioterrorism. The company is a subsidiary of Southwest Research Institute and is committed to community engagement and workforce development.

PDV MedTech, previously known as Phoenix DeVentures, is a U.S.-based company founded in 2001 specializing in medical device design, development, and ISO 13485:2016-certified contract manufacturing. Acquired by INDO-MIM in 2025, the company offers end-to-end solutions from prototyping to high-volume production with capabilities in injection molding, 3D printing, fabrication of mold tools, and cleanroom assembly. PDV MedTech supports startups and innovators in commercializing their devices through regulatory support, quality management, and scalable manufacturing across locations in California, Colorado, and Utah.